Ospedale San Raffaele · company speakers →
Dr. Chiara Bonini will discuss how the development of genetic engineering technologies dramatically changed the landscape of adoptive T cell therapy (ACT) for cancer, making this treatment accessible to an unprecedent number of patients and tumor types. By inserting a CAR or an exogeneous tumor reactive T cell receptor into patient’s T cells, the specificity can be precisely redirected toward selected tumor antigens. Gene disruption, targeted gene integration, and genome editing tools have further increased the range of opportunities for ACT. With selected biotechnological tools and protocols, we could potentially endow T cells with the ability to infiltrate the tumor mass, recognize relevant tumor antigens, resist the immunosuppressive signals present in the tumor microenvironment and persist as memory cells, to patrol the organism for recurrence. Dr. Bonini will discuss challenges and opportunities towards the generation of optimal T cell therapy products.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →